Company
Context Therapeutics
NASDAQ:CNTX
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Additionally, the company is advancing onapristone extended release (ONA-XR), a novel, first-in-class, potent, and selective progesterone receptor antagonist, currently in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancers. Context is headquartered in Philadelphia.
32 stories
Fokus Mining stock jumps on gold drill results plus more daily small cap movers
Long intersections of drilled gold boosted shares of Fokus Mining Corporation Tuesday plus other big percentage movers on news from the small and micro cap space
Context Therapeutics ends 3Q with a substantial $39M cash runway to advance pipeline programs
“Our expected cash runway into 1Q 2024 gives us the financial flexibility to execute on the advancement of our pipeline targeting female cancers,” said Context Therapeutics CEO Martin Lehr
Context Therapeutics CEO charts path for fiscal stability into 2024, tightens focus on Phase 1b ELONA breast cancer trial
“We are streamlining the organization’s resources with the intent to take the company through the execution of the Phase 1b portion of the ELONA trial and the advancement of our CLDN6xCD3 bispecific antibody program,” CEO Martin Lehr said
Context Therapeutics ends 2Q with strong $42.9M cash runway to advance pipeline programs
“During the second quarter, Context continued to advance its two pipeline programs, onapristone extended release (ONA-XR) and Claudin 6 x CD3 (CLDN6xCD3) bispecific antibody,” said Context Therapeutics CEO Martin Lehr
Context Therapeutics collaborates with Menarini Group to evaluate ONA-XR and elacestrant combination
The women’s oncology company said the agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release in combination with elacestrant in estrogen receptor positive, PR+ HER2- meta
Context Therapeutics ends 1Q with $45.7M as it gears up for 'pivotal' 2022
The women’s oncology company said its cash and equivalents on hand should be sufficient to fund its operations into 2024
Context Therapeutics announces poster presentation at upcoming 2022 ASCO annual meeting
"We are thrilled that ASCO has recognized the potential of our novel clinical program for ONA-XR, a potent, specific progesterone receptor (PR) antagonist, in the treatment of granulosa cell tumors (GCTs) of the ovary," the company’s CEO Ma
Context Therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programs
The women’s oncology company said the lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrated strong efficacy across multiple PR+ solid tumor models
Context Therapeutics closes 2021 with balance sheet of nearly $50M
The women's oncology company expects its cash balance will be sufficient to fund operations into 2024
Context Therapeutics to showcase its compounds at this year's American Association for Cancer Research (AACR) annual meeting
Five abstracts have been selected for poster or symposium presentations at the event in New Orleans, Louisiana
Edison Investment Research initiates coverage of Context Therapeutics with valuation of $8.45 per share
“With multiple data readouts expected in 2022, we foresee several inflection points in the coming months,” Edison analysts said
Context Therapeutics prepares for a busy 2022 as it advances women’s oncology treatments
The clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancer
Context Therapeutics adds two new executives to strengthen its research and development team
Christopher Beck will take on the role of senior vice president of operations and Mark Fletcher will be the firm’s new vice president of R&D
Context Therapeutics announces positive data from Onapristone extended release in early breast cancer
“This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers,” said Martin Lehr, CEO of Context Therapeutic
Context Therapeutics closes its $31.3M private placement
The company issued 5 million of its common shares, at a price of $6.25 each, plus 5 million common share purchase warrants with a five-and-one-half year term and an exercise price of $6.25 per share
Archive
NA Proactive news snapshot: Marvel Discovery, Bluerush, Champion Gaming, Vuzix Corporation, Psyence Group, Context Therapeutics UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Context Therapeutics reports 3Q results during a “pivotal” period for the company
The women’s oncology company debuted on Nasdaq and entered into a $31.25 million private placement agreement that extends its cash runway into 2024
IPO Roundup: Non-opioid pain treatment developer Centrexion Therapeutics set to IPO
The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler